[Study on the Effect of Treatment Regiman Combined with Ruxolitinib on MPN Patients with Myelofibrosis and the Influencing Factors of Mutated Gene Load].

OBJECTIVE

To investigate the efficacy of ruxolitinib combined regimen in the treatment of myeloproliferative neoplasm (MPN) with myelofibrosis (MF) and its effect on mutated gene load.

METHODS

The clinical data of 79 MPN patients with MF were retrospectively collected from the Department of Hematology of Shanghai Sixth People's Hospital from January 2022 to November 2024 to explore the effect of combined treatment with ruxolitinib, the change of mutated gene load after treatment, and the relationship between them.

RESULTS

Ruxolitinib combined with thalidomide, prednisone, androgen, interferon and other drugs could significantly improve the clinical symptoms of MF patients, shrink the spleen, and patients reaching spleen volume reduction of 35% (SVR35) accounted for 45.5% of all patients with splenomegaly. The JAK2 mutation load was significantly reduced in patients treated with regular interferon alpha therapy. In patients with low JAK2 mutation load, the presence or absence of high molecular risk mutation was the main factor affecting SVR35.

CONCLUSION

Ruxolitinib combined with thalidomide, prednisone, androgen, interferon alpha and other drugs can improve the clinical symptoms of MPN patients with MF, shrink the spleen, and also have a positive effect on reducing the JAK2 mutation load.